Roche and GlaxoSmithKline osteoporosis treatment heads to clearance

Bonviva (ibandronic acid), co-developed and co-promoted by Roche and GlaxoSmithKline (GSK), has been recommended for approval in the EU by the Committee for Medicinal Products for Human Use (CHMP).

Once approved, Bonviva is set to be the first IV injection for the treatment of osteoporosis in postmenopausal women available in the EU.

Roche global head for Bonviva Peter Matton said: “We know there is a specific group of women who are unable to take oral bisphosphonates. This new quarterly injection of Bonviva allows them to also benefit from this effective class of osteoporosis treatment.”

Pierre Delmas, professor of medicine and rheumatology, said: “Oral bisphosphonates are the most commonly prescribed treatment for postmenopausal osteoporosis.

“Furthermore, recent studies have shown women prefer Bonviva once-monthly to once-weekly oral bisphosphonate treatment, finding it more convenient.

“However, for those women who cannot take oral medication, a quarterly injection of Bonviva would provide healthcare professionals with an important, alternative treatment option.”

GSK and Roche have been collaborating to develop and market Bonviva since 2001 and their agreement covers most major markets, except Japan.

© Adfero Ltd